GSK PLC (LSE:GSK, NYSE:GSK) has taken a step towards widening access to its respiratory syncytial virus (RSV) vaccine in Europe, with the European Medicines Agency accepting its application to expand the vaccine’s use to all adults aged 18 and over.
The vaccine, sold under the name Arexvy, is already authorised across Europe for adults aged 60 and over, as well as those aged 50 to 59 who are at increased risk due to underlying health conditions.
If approved, the latest submission would significantly broaden the eligible population.
RSV is a highly contagious respiratory virus that poses serious health risks, particularly for older adults or those with chronic conditions such as asthma or heart failure. It can lead to complications, including pneumonia and hospitalisation.
Arexvy uses a stabilised RSV protein paired with an immune-boosting adjuvant to trigger a stronger response.
A decision from European regulators is expected in the first half of 2026, with GSK also pursuing approval in the US and Japan.